A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

NCT05276310 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

BIOLOGICAL: IMC-002

Sponsor

ImmuneOncia Therapeutics Inc.